Want to join the conversation?
Marc Goodman of UBS asks about gross margins in the generics business. $ENDP said the gross margins held up right in line with expectations. The company set full-year guidance of generics GM in the low 50s and this was the level achieved in 2Q16. The outlook remains consistent for the full year.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.